KR20200062242A - 모발 성장을 조절하는 조성물 및 방법 - Google Patents

모발 성장을 조절하는 조성물 및 방법 Download PDF

Info

Publication number
KR20200062242A
KR20200062242A KR1020207011209A KR20207011209A KR20200062242A KR 20200062242 A KR20200062242 A KR 20200062242A KR 1020207011209 A KR1020207011209 A KR 1020207011209A KR 20207011209 A KR20207011209 A KR 20207011209A KR 20200062242 A KR20200062242 A KR 20200062242A
Authority
KR
South Korea
Prior art keywords
acid
pharmaceutical composition
inhibitor
electron transport
transport chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207011209A
Other languages
English (en)
Korean (ko)
Inventor
윌리암 이. 로우리
헤더 알. 크리스토프크
마틸다 미랜더
에이미 플로레스
Original Assignee
더 리전트 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리전트 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리전트 오브 더 유니버시티 오브 캘리포니아
Publication of KR20200062242A publication Critical patent/KR20200062242A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
KR1020207011209A 2017-09-29 2018-09-28 모발 성장을 조절하는 조성물 및 방법 Ceased KR20200062242A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566031P 2017-09-29 2017-09-29
US62/566,031 2017-09-29
PCT/US2018/053351 WO2019067860A1 (en) 2017-09-29 2018-09-28 COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH

Publications (1)

Publication Number Publication Date
KR20200062242A true KR20200062242A (ko) 2020-06-03

Family

ID=65903207

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011209A Ceased KR20200062242A (ko) 2017-09-29 2018-09-28 모발 성장을 조절하는 조성물 및 방법

Country Status (16)

Country Link
US (1) US20200253917A1 (enExample)
EP (1) EP3687528A4 (enExample)
JP (1) JP2020536048A (enExample)
KR (1) KR20200062242A (enExample)
CN (1) CN111295188A (enExample)
AU (1) AU2018339064A1 (enExample)
BR (1) BR112020003349A2 (enExample)
CA (1) CA3077359A1 (enExample)
CL (1) CL2020000676A1 (enExample)
EA (1) EA202090855A1 (enExample)
IL (1) IL272827A (enExample)
MX (1) MX2020002389A (enExample)
PE (1) PE20210464A1 (enExample)
PH (1) PH12020500300A1 (enExample)
SG (2) SG10202109849SA (enExample)
WO (1) WO2019067860A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216071A1 (ko) * 2021-04-09 2022-10-13 차의과학대학교 산학협력단 세팔로틴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 탈모방지 또는 발모촉진용 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102440809B1 (ko) 2017-02-24 2022-09-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 Mpc 저해제를 사용하여 모발 성장을 촉진하는 조성물 및 방법
IL321754A (en) 2017-06-30 2025-08-01 Univ California Compositions and methods for modulating hair growth
US12649736B2 (en) 2019-12-20 2026-06-09 The Regents Of The University Of California Synthesis of compounds to promote hair growth
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth
CN113694063A (zh) * 2021-08-31 2021-11-26 佛山市第一人民医院（中山大学附属佛山医院） 一种组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
ES2312012T3 (es) * 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
EP1919449A2 (en) * 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8343962B2 (en) * 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US9308181B2 (en) * 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8563500B2 (en) * 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
CN106880693A (zh) * 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216071A1 (ko) * 2021-04-09 2022-10-13 차의과학대학교 산학협력단 세팔로틴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 탈모방지 또는 발모촉진용 조성물

Also Published As

Publication number Publication date
AU2018339064A1 (en) 2020-02-27
JP2020536048A (ja) 2020-12-10
CA3077359A1 (en) 2019-04-04
EP3687528A1 (en) 2020-08-05
CN111295188A (zh) 2020-06-16
EA202090855A1 (ru) 2020-06-26
BR112020003349A2 (pt) 2020-08-18
WO2019067860A1 (en) 2019-04-04
PE20210464A1 (es) 2021-03-08
IL272827A (en) 2020-04-30
PH12020500300A1 (en) 2020-11-09
MX2020002389A (es) 2020-10-01
EP3687528A4 (en) 2021-07-21
SG10202109849SA (en) 2021-10-28
CL2020000676A1 (es) 2020-09-25
SG11202001516QA (en) 2020-03-30
US20200253917A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
US12310983B2 (en) Method of administration and treatment
US20200253917A1 (en) Compositions and methods for modulating hair growth
JP5875191B2 (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
Adamson et al. Assessment of carprofen and buprenorphine on recovery of mice after surgical removal of the mammary fat pad
EA023380B1 (ru) Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений
BR112021004542A2 (pt) inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos
JP2022504771A (ja) 健康寿命延長を目的とするニコチンアミドリボシド組成物
EP2862572B1 (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
US20230040125A1 (en) Targeting the intrinsic apoptotic machinery in glioblastoma
US20110065674A1 (en) Methods and compositions for improving cognitive function
EP4539808A1 (en) A benzimidazole compound with antihelminthic activity for use in reversing, arresting or slowing down cellular ageing in a vertebrate subject
HK40026046A (en) Compositions and methods for modulating hair growth
CN101448514A (zh) 黑素瘤的治疗
WO2016145488A1 (en) Treatment of skin conditions
US20230321004A1 (en) Methods and Compositions for Treating Melanoma and Non-Melanoma Skin Cancers
WO2020242910A1 (en) Compositions and methods for treating cancer
CN119698284A (zh) 用于治疗X-ALD的甲状腺β激动剂给药方案
HK40123938A (en) Thyroid beta-agonist dosing regimens for the treatment of x-ald
EA017028B1 (ru) Антибактериальная композиция
WO2025166338A2 (en) Systemic mpc inhibition to reverse signs of aging
WO2025117739A1 (en) Compositions and methods for treating cancer
KR20260071462A (ko) 동물의 피부 질환 치료용 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200417

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240422

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240708

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D